卵巢癌中的肿瘤抗原性
Tumour antigenicity in ovarian cancer.
作者信息
Levin L, McHardy J E, Curling O M, Hudson C N
出版信息
Br J Cancer. 1975 Aug;32(2):152-9. doi: 10.1038/bjc.1975.144.
The blastogenic response to a crude cell extract of ovarian cancer cells has been studied in 48 patients with ovarian cancer (9, autologous, 39 allogeneic), in 26 female controls matched for age and in 18 female patients with other types of cancer in remission from disease. The responses in ovarian cancer patients in remission and relapse were considered separately. The blastogenic responses to cell extracts of foetal ovary, foetal lung, foetal liver and normal adult ovary were also assessed in a proportion of all 3 groups. The blastogenic responses to ovarian cancer and foetal ovary cell extracts were found to be significantly greater in the ovarian cancer patients in remission than in the controls, but the responses to ovarian cancer extract were not greater in the relapse group or in patients with other cancers. As a blastogenic response to normal ovarian extract was also present in some of these patients, the data so far do not support the hypothesis of a tumour specific antigen. This tumour associated response may be occurring to determinants in foetal or adult ovarian tissue to which the patient becomes sensitized in malignant disease. The response is complex and the nature of the antigen requires further analysis.
对48例卵巢癌患者（9例自体，39例异体）、26例年龄匹配的女性对照以及18例处于疾病缓解期的其他类型癌症女性患者，研究了其对卵巢癌细胞粗细胞提取物的增殖反应。对处于缓解期和复发期的卵巢癌患者的反应分别进行了研究。还在所有3组中的一部分患者中评估了对胎儿卵巢、胎儿肺、胎儿肝脏和正常成年卵巢细胞提取物的增殖反应。结果发现，处于缓解期的卵巢癌患者对卵巢癌和胎儿卵巢细胞提取物的增殖反应明显高于对照组，但复发组或其他癌症患者对卵巢癌提取物的反应并不更高。由于其中一些患者对正常卵巢提取物也有增殖反应，目前的数据不支持肿瘤特异性抗原的假说。这种肿瘤相关反应可能是针对胎儿或成年卵巢组织中的决定簇发生的，患者在恶性疾病中对这些决定簇产生了致敏。该反应很复杂，抗原的性质需要进一步分析。
Zotero 插件